Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. 2009

Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
Cardiovascular Medicine Department, Foundation G. Monasterio, CNR-Regione Toscana, Pisa, Italy. emdin@ifc.cnr.it

BACKGROUND Serum gamma-glutamyltransferase activity (GGT) has been documented as an independent cardiovascular risk factor. However, to-date its value has not been compared with C-reactive protein (CRP) and other indexes in a multimarker prognostic strategy in patients with coronary artery disease. METHODS We prospectively evaluated 474 subjects with angiographically documented CAD. GGT and traditional humoral and clinical parameters were measured at hospital admission. A multivariate model was used to predict all-cause and cardiac mortality. RESULTS GGT showed an independent prognostic value after adjustment for possible confounders, including alcohol consumption, and beyond established risk factors, such as extent of coronary atherosclerotic disease, left ventricular ejection fraction, age, serum glucose, cholesterol subfractions, and C-reactive protein (CRP). At a 3-year follow-up, cardiac mortality was 9% in patients with serum GGT activity >25 U/L vs. 3.5% in those with serum GGT<25 U/L (p=0.028). The association of three independent biomarkers (higher GGT, CRP, fasting glucose) identified a subgroup of 45 patients with the highest risk of cardiac death at 3 years (26.6%, vs. no event or 2.7% in the subsets of 87 and 198 patients with, respectively, no/one risk factor above cut-off value, p<0.0001). CONCLUSIONS GGT is confirmed as independent risk factor in patients with established coronary artery disease. GGT, CRP, fasting glucose show an additive prognostic value, whereas low values of these biomarkers identify a subset of patients with the lowest risk of cardiac death.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005723 gamma-Glutamyltransferase An enzyme, sometimes called GGT, with a key role in the synthesis and degradation of GLUTATHIONE; (GSH, a tripeptide that protects cells from many toxins). It catalyzes the transfer of the gamma-glutamyl moiety to an acceptor amino acid. GGTP,Glutamyl Transpeptidase,gammaglutamyltransferase,gamma-Glutamyl Transpeptidase,Transpeptidase, Glutamyl,Transpeptidase, gamma-Glutamyl,gamma Glutamyl Transpeptidase,gamma Glutamyltransferase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
July 2017, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
April 2009, Clinical cardiology,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
August 2013, International journal of cardiology,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
January 2013, Angiology,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
March 2015, The American journal of cardiology,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
January 2022, Annals of cardiac anaesthesia,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
October 2016, Clinical biochemistry,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
April 2011, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
December 1999, The American journal of cardiology,
Michele Emdin, and Claudio Passino, and Claudio Michelassi, and Luigi Donato, and Alfonso Pompella, and Aldo Paolicchi
January 2020, Frontiers in cardiovascular medicine,
Copied contents to your clipboard!